Publications

Genomic and biomarker landscape of MTAP deficiency in gastrointestinal cancers.

R Thummalapalli, J Xu, N Tezcan, A Dhyani, OM Fitzpatrick, F Nagib, ...

Genomic evolution of pancreatic cancer at single-cell resolution

Zhang H, Sashittal P, Karnoub ER, Jakatdar A, Umeda S, Hong J, Noronha AM, Cardenas A 3rd, et al.

Genomic landscape and clinical outcomes of MDM2 amplifications in biliary tract cancers.

F Nagib, S Nasir, A Dhyani, R Thummalapalli, DN Khalil, O Heffernan, ...

Genomic predictors of pathologic response to hepatic artery infusion pump chemotherapy in colorectal liver metastases

N Nasar, JF Chou, J Datta, MT Evenhaim, M Gonen, KC Soares, ...

Germline Pathogenic Variants in Homologous Recombination Pathway Genes Are Frequent in Pancreatobiliary Ampullary Carcinoma

Misyura M, Selenica P, Ozcan K, Kemel Y, Basturk O, O'Reilly EM, Reis-Filho JS, Beets-Tan R, et al.

Health-related quality of life (HRQOL) in the phase 3 trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III …

AC Dueck, B Fruth, AC Reinacher-Schick, W Peters, RJ Behrens, C Lieu, ...

Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials

M Rousian, R Alessandris, L Schleimer, H Kalvin, O Zaki, L Connell, ...

IL10R Inhibition Induces Neutrophil Tumoricidal Activity

Khalil DN, Gomez R, Regev A, Samaan F, Marouf Y, Budhu S, Hirschhorn D, Schulze I, et al.

Image registration improves inter-reader agreement of objective response in CT assessment of pancreas adenocarcinoma

JS Heiselman, N Horvat, M El Homsi, B Agridag-Ucpinar, O Yildirim, ...

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial

Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, et al.

Investigating Age-Related Differences in Survival Outcomes and Mutation Status of Patients with Intrahepatic Cholangiocarcinoma: M. Armstrong et al.

M Armstrong, H Kalvin, M Gönen, G Abou-Alfa, VP Balachandran, ...

Invigorating pre-existing tumor-infiltrating expandable (TIE) T cell clonotypes in exceptional responders with dual PARP-PD-1 blockade in homologous recombination deficient …

M Hilmi, W Mckerrow, JD Schoenfeld, S Umeda, N Tezcan, C O'Connor, ...

Lycopene and survival in patients with stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702.

S Lee, Q Shi, C Ma, P Kumar, F Couture, JP Kuebler, SS Krishnamurthi, ...

Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial

Reyngold M, Wei AC, O'Reilly EM, D'Angelica MI, Kingham TP, Soares KC, Varghese AM, White C, et al.

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, Shah F, Huq R, Thummalapalli R, Nagib F, Varghese A, et al.

Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer

W Quan, D Henault, A Zhang, GH Jang, SM Hasnain, D Bevacqua, ...

Mutant allele copy number gains define distinct molecular subtypes of oncogene-driven cancers and are associated with response to allele-specific KRAS G12C inhibitor sotorasib …

MA Perry, AL Richards, A Price, SE Tischfield, H Walch, H Xie, ...

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial

T Macarulla, RP Cid, MS Womack, AC Gracian, A Zervoudakis, H Hatoum, ...

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

M Hilmi, JD Schoenfeld, W McKerrow, Y Elhanati, CA O'Connor, S Umeda, ...

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer

Schram AM, Yang SR, Kahn G, Velasco R, Repetto M, Kinh Gian Do R, DiNapoli S, Sukhadia P, et al.

Oncogene Mutations: The Shared Antigen Vaccines That Work?

R Paredes, SD Haldar, S Pant, EM O'Reilly

Organotropic and genomic characterization of pancreatic neuroendocrine carcinoma.

S Wallam, CJ Kinslow, R Thummalapalli, AA Wallam, DP Horowitz, ...

Outcomes of First Versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

Nasar N, Armstrong M, Chou JF, Gonen M, Soares KC, Balachandran VP, Drebin JA, Kingham TP, et al.

Pancreatic cancer

Roth S, Apte M, Balachandran VP, Biffi G, Conroy T, Cukierman E, Dotan E, Esposito I, et al.

Pancreatic Cancer—Advances in the Last 50 Years

SG Barreto, A Maitra, EM O'Reilly, D Sahani, R Zheng, CJ Yeo

Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms

O'Reilly EM

Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms: Pancreatic cancer in 2025

EM O’Reilly

Pancreatic Cancer: Translating Tumor Biology into Actionability

Balogun FO, Sherman MH, Park W, Soares KC, Reyngold M, Schoenfeld JD, Singhal A, Iacobuzio-Donahue CA, et al.

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

W Park, CA O’Connor, JF Chou, M Hilmi, Z Tarcan, C Schwartz, M Larsen, ...

Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR Trial

Park W (Corresponding Author), O’Reilly E, et al.

Physical activity and molecular residual disease in stage III colon cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702

GQ Zhang, C Ma, VB Yang, Q Shi, JA Nowak, L Pederson, T Twombly, ...

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

Park W, Umeda S, Hilmi M, O'Connor C, Sharma R, Tezcan N, Zhang H, Zhu Y, et al.

Precision oncology in pancreatic cancer and future treatment directions

L Al Mahmasani, EM O’Reilly

Predictive biomarkers of systemic treatment in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials.

CA McIntyre, E Dekker, M Gonen, MG Besselink, MYV Homs, B Mostert, ...

Predictive role of circulating tumor DNA in stage III colon cancer treated with celecoxib: a post hoc analysis of the CALGB (Alliance)/SWOG 80702 phase 3 randomized clinical trial

GQ Zhang, JA Meyerhardt, Q Shi, T Twombly, L Pederson, C Ma, ...

Prognostic value of CT radiomics in patients with gBRCA1/2 and PALB2 and advanced pancreas cancer.

S Gandhi, J Chakraborty, H Ghahremannezhad, R Do, N Horvat, KH Yu, ...

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, et al.

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer

MN Karam, J Hajj, CH Crane, P Ramia, F Geara, N Hamadeh, JG Scott, ...

Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2 …

V Chung, KA Guthrie, MJ Pishvaian, AM Lowy, D Sohal, S Colby, ...

Response to Letter to the Editor:‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of …

T Macarulla, RP Cid, MS Womack, AC Gracian, A Zervoudakis, H Hatoum, ...

Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium

EN Dekker, D van Klaveren, EMM Verkolf, RF de Wilde, MG Besselink, ...

Safety and Feasibility of Intra-Arterial Treatment of Pancreatic Cancer Using an Emulsion of Ethiodized Oil plus Bumetanide in an Oncopig Model

H Yarmohammadi, SY Son, AWP Maxwell, AS Elsakka, VS Sotirchos, ...

Su1848 ENDOSCOPIC ULTRASOUND-GUIDED BIOMARKER EVALUATION OF PANCREATIC CANCER AFTER EXPOSURE TO THERAPY

SE Lee, D Kim, VS Rolston, E Vakiani, C Sigel, EM O’Reilly, K Yu, ...

Target Antigen Identification for Antibody Drug Conjugate Therapy in Biliary Tract Cancer

A Dhyani, N Tezcan, JF Chou, Z Tarcan, R Thummalapalli, F Nagib, ...

Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Documentation

Cardell CF, Segovia D, Prakash LR, Zemla T, Shi Q, Ahmad S, Herman JM, O'Reilly EM, et al.

The Development of Second-Generation KRAS Inhibitors

EM O’Reilly

The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer

CS Leonhardt, M Adham, S Bazarbashi, I Ben-Aharon, RGH Beets-Tan, ...

Tracking genomic evolution in ERBB2-altered biliary tract cancer through longitudinal tumor profiling.

OM Fitzpatrick, D Cowzer, R Thummalapalli, J Chou, F Nagib, M Dunphy, ...

Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer

Jiménez-Sánchez A, Persad S, Hayashi A, Umeda S, Sharma R, Xie Y, Mehta A, Park W, et al.

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here

May MS, Park W, O'Reilly EM